Vanda Pharmaceuticals (VNDA)’ treatment of polycythemia vera was granted FDA orphan designation, according to a post to the agency’s site.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda seeks FDA Commissioner review of Hetlioz generic ruling
- Vanda Pharmaceuticals’ Legal Victory and Potential HETLIOZ Approval Boosts Buy Rating
- Vanda Pharma granted favourable Court ruling over FDA’s Hetlioz approvability
- Strong Buy Rating for Vanda Pharmaceuticals Driven by Growth in Key Product Lines and Promising FDA Decision
- Vanda Pharmaceuticals’ Earnings Call: Growth Amid Challenges